Radium-223 mechanism of action: implications for use in treatment combinations

Volume: 16, Issue: 12, Pages: 745 - 756
Published: Nov 11, 2019
Abstract
The targeted alpha therapy radium-223 (223Ra) can prolong survival in men with castration-resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known visceral metastases. Preclinical studies demonstrate that 223Ra preferentially incorporates into newly formed bone matrix within osteoblastic metastatic lesions. The emitted high-energy alpha particles induce DNA double-strand breaks that might be irreparable and lead to cell...
Paper Details
Title
Radium-223 mechanism of action: implications for use in treatment combinations
Published Date
Nov 11, 2019
Volume
16
Issue
12
Pages
745 - 756
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.